Equis ISSN 2398-2977

Dantrolene

Synonym(s): Dantrolene sodium, Dantrium

Contributor(s): Adam Auckburally, Jessica A Kidd-Millar

Introduction

Name

  • Dantrolene.

Class of drug

  • Muscle relaxant.

Description

Chemical name

  • Dantrolene sodium.

Molecular formula

  • C14H10N4O5.

Molecular weight

  • 314.253 g/mol.

Physical properties

  • Orange powder, slightly soluble in water, but due to its slightly acidic nature the solubility increases somewhat in alkaline solution.

Storage requirements

  • Capsules: should be stored at room temperature in a closed container.
  • Intravenous preparation:
    • Powder to be reconstituted before injection.
    • Store at temperatures <30°C.
    • Once reconstituted, protect from light and use within 6 h.
    • Reconstitution should not be performed with saline or dextrose solutions.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • In humans, neuromuscular blockade is potentiated when used with other neuromuscular blocking agents.

Sedative   Anesthesia: standing chemical restraint  effects can be potentiated by CNS depressants.

Use with benzodiazepines (such as diazepam   Diazepam  ) may increase muscular weakness and sedation.

Calcium channel blockers should not be used in conjunction with dantrolene for the treatment of malignant hyperthermia.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • McKenzie E C et al (2004) Effect of oral dantrolene sodium on creatinine kinase activity after exercise in horses with recurrent exertional rhabdomyolysis. Am J Vet Res 65, 74-79 PubMed.
  • Edwards J G, Newtont J R, Ramzan P H, Pilsworth R C & Shepherd M C (2003) The efficacy of dantrolene sodium in controlling exertional rhabdomyolysis in the Thoroughbred racehorse. Equine Vet J 35, 707-711 PubMed.

Other sources of information

  • Schreiber (2011) Practical use of Dantrium. In: BEVA Proc. pp 23.
  • DiMaio K et al (2010) Comparative Pharmacokinetics of Two Oral Formulations of Dantrolene in the Horse. In: AAEP Proc.Vol 56. pp 53.
  • PlumPlumbs Veterinary Drug Handbook (2008) 6th edn. Ed: Plumb D. Blackwell Publishing, USA.
  • Product Monograph (2008) Dantrium Capsules. JHP Pharmaceuticals.
  • Valberg S J, McCue M E & Mickelson J R (2008) A Review of Genetic Muscle Disorders in Foals of Quarterhorse Related Breeds. In: Proc AAEP Focus Meeting: First Year of Life. pp 29-36.

ADDED